Comparative Efficacy and Safety of Lorlatinib vs. Alectinib and Lorlatinib vs. Brigatinib for ALK-positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons

The comparative efficacy and safety of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), versus second-generation ALK TKIs as a first-line treatment for ALK+ advanced/metastatic nonsmall cell lung cancer (NSCLC) remains uncertain as there are no head-to-head clinical trials.